Clinical Trials (Phases I–IV)

16+ hour, 21+ min ago   (173+ words) Bristol Myers Squibb (BMY), a biopharmaceutical company, announced Monday the topline results from its pivotal Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis (IPF). Admilparant is a potential first-in-class, orally administered lysophosphatidic acid receptor 1 (LPA1) antagonist. The trial…...

11+ hour, 34+ min ago   (662+ words) Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has premiered a new short film as part of a campaign to raise awareness of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, two progressive lung conditions that can have a profound impact on…...

6+ hour, 32+ min ago   (687+ words) AstraZeneca has already filed for approval of its therapy for ultra-rare disease hypophosphatasia (HPP), after missing the mark in a phase 3 trial, but reckons the totality of the data could get the drug over the line with a broad label....

1+ hour, 58+ min ago   (290+ words) With three FDA-approved biologics for hidradenitis suppurativa, Jennifer Hsiao, M.D., said patient preference and access often decide which comes first. Dermatologists treating hidradenitis suppurativa (HS) now have three FDA-approved biologics to choose from. Deciding which one to start tends to come…...

1+ hour, 59+ min ago   (401+ words) Patients with HS should get three to four months on a biologic before a switch, says a dermatologist who sees promise in oral JAK inhibitors. Patients starting a biologic for hidradenitis suppurativa (HS) need to know up front that results…...

2+ hour, 20+ min ago   (171+ words) Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place. “Obesity is not the reason for HS. It is a part of your HS, and HS is not…...

2+ hour, 25+ min ago   (269+ words) In a striking finding, 97% of patients who had experienced no facial repigmentation whatsoever at week 24 demonstrated measurable F-VASI improvement after 104 weeks of continuous ruxolitinib cream use. The clinically meaningful threshold of 75% or greater improvement in F-VASI — considered a significant benchmark…...

2+ hour, 36+ min ago   (646+ words) Intel Accelerates Open Infrastructure for the Agentic AI Era Rates of treatment-emergent adverse events leading to treatment discontinuation were low in both MAXPIRe trial arms. Syndax Pharmaceuticals (SNDX) announced that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis…...

2+ hour, 46+ min ago   (441+ words) REGENXBIO Inc. announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgenelomparvovec in diabetic retinopathy using suprachoroidal delivery. These......

3+ hour, 7+ min ago   (458+ words) Efzimfotase alfa missed significance on the six-minute walk test in adolescents and adults, while the FDA review of the therapy proceeds toward 2027. The FDA is reviewing a biologics license application for the drug under priority review, with an action date…...